These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Overprolonged adjuvant tamoxifen therapy in breast cancer. Stoll BA Ann Oncol; 1991 Jun; 2(6):401-3. PubMed ID: 1768625 [TBL] [Abstract][Full Text] [Related]
24. Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients--longterm follow-up. Fjøsne HE; Jacobsen AB; Lundgren S; Eur J Surg Oncol; 2008 Jan; 34(1):6-12. PubMed ID: 17881183 [TBL] [Abstract][Full Text] [Related]
25. Megestrol melanoma study. Nathanson L; Garrison M World J Surg; 1995; 19(3):337-42. PubMed ID: 7638983 [TBL] [Abstract][Full Text] [Related]
26. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Ross MB; Buzdar AU; Blumenschein GR Cancer; 1982 Feb; 49(3):413-7. PubMed ID: 6174195 [TBL] [Abstract][Full Text] [Related]
27. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Fiorica JV; Brunetto VL; Hanjani P; Lentz SS; Mannel R; Andersen W; Gynecol Oncol; 2004 Jan; 92(1):10-4. PubMed ID: 14751131 [TBL] [Abstract][Full Text] [Related]
28. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Morgan LR Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652 [TBL] [Abstract][Full Text] [Related]
29. High-dose megestrol acetate as third-line endocrine therapy for metastatic breast cancer. Cruz JM; Muss HB; Russell G Oncology; 1992; 49 Suppl 2():8-11. PubMed ID: 1461630 [TBL] [Abstract][Full Text] [Related]
30. Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Andersen J; Kamby C; Ejlertsen B; Cold S; Ewertz M; Jacobsen EH; Philip P; Møller KA; Jensen D; Møller S Acta Oncol; 2008; 47(4):718-24. PubMed ID: 18465340 [TBL] [Abstract][Full Text] [Related]
31. High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities. Aisner J; Tchekmedyian NS; Moody M; Tait N Semin Hematol; 1987 Apr; 24(2 Suppl 1):48-55. PubMed ID: 3589708 [TBL] [Abstract][Full Text] [Related]
32. Megestrol acetate: a new role in the treatment of metastatic breast cancer. Allegra JC Semin Hematol; 1987 Apr; 24(2 Suppl 1):45-7. PubMed ID: 3589707 [TBL] [Abstract][Full Text] [Related]
33. Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids. Löfgren L; Wallberg B; Wilking N; Fornander T; Rutqvist LE; Carlström K; von Schoultz B; von Schoultz E Med Oncol; 2004; 21(4):309-18. PubMed ID: 15579914 [TBL] [Abstract][Full Text] [Related]
34. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Ettinger DS; Allegra J; Bertino JR; Bonomi P; Browder H; Byrne P; Carpenter J; Catalano R; Creech R; Dana B Semin Oncol; 1986 Dec; 13(4 Suppl 4):9-14. PubMed ID: 3026052 [TBL] [Abstract][Full Text] [Related]
35. Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. Horton J; Knuiman M; Keller AM; Vogel H; Gale KE; Hahn RG; Rosenbluth RJ; Tormey DC Cancer; 1987 Nov; 60(9):2137-40. PubMed ID: 3440224 [TBL] [Abstract][Full Text] [Related]
36. High-dose megestrol acetate in the treatment of advanced breast cancer. Tchekmedyian NS; Tait N; Abrams J; Aisner J Semin Oncol; 1988 Apr; 15(2 Suppl 1):44-9. PubMed ID: 3368800 [TBL] [Abstract][Full Text] [Related]
37. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711 [TBL] [Abstract][Full Text] [Related]
38. Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: therapeutic and endocrine effects in postmenopausal advanced breast cancer patients. Gasparini G; Canobbio L; Galligioni E; Fassio T; Brema F; Crivellari D; Villalta D; Di Fronzo G; Talamini R; Monfardini S Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1451-9. PubMed ID: 2960532 [TBL] [Abstract][Full Text] [Related]
40. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]